BrightAccountsProduction v1.0.0 v1.0.0 2023-01-01 The company was not dormant during the period The company was trading for the entire period Unaudited Accounts The principal activity of the company is the provision of services to compliment patient centered care 21 August 2024 NI642637 2023-12-31 NI642637 2022-12-31 NI642637 2021-12-31 NI642637 2023-01-01 2023-12-31 NI642637 2022-01-01 2022-12-31 NI642637 uk-bus:PrivateLimitedCompanyLtd 2023-01-01 2023-12-31 NI642637 uk-curr:PoundSterling 2023-01-01 2023-12-31 NI642637 uk-bus:FullAccounts 2023-01-01 2023-12-31 NI642637 uk-bus:Director1 2023-01-01 2023-12-31 NI642637 uk-bus:RegisteredOffice 2023-01-01 2023-12-31 NI642637 uk-bus:Agent1 2023-01-01 2023-12-31 NI642637 uk-core:ShareCapital 2023-12-31 NI642637 uk-core:ShareCapital 2022-12-31 NI642637 uk-core:RetainedEarningsAccumulatedLosses 2023-12-31 NI642637 uk-core:RetainedEarningsAccumulatedLosses 2022-12-31 NI642637 uk-core:TotalEquityAttributableToOwnersParentBeforeNon-controllingInterests 2023-12-31 NI642637 uk-core:TotalEquityAttributableToOwnersParentBeforeNon-controllingInterests 2022-12-31 NI642637 uk-bus:FRS102 2023-01-01 2023-12-31 NI642637 uk-core:FurnitureFittingsToolsEquipment 2023-01-01 2023-12-31 NI642637 uk-core:CurrentFinancialInstruments 2023-12-31 NI642637 uk-core:CurrentFinancialInstruments 2022-12-31 NI642637 uk-core:WithinOneYear 2023-12-31 NI642637 uk-core:WithinOneYear 2022-12-31 NI642637 2023-01-01 2023-12-31 NI642637 uk-bus:AuditExempt-NoAccountantsReport 2023-01-01 2023-12-31 xbrli:pure iso4217:GBP xbrli:shares
 
 
 
Screen Clinical Limited
 
Director's Report and Unaudited Financial Statements
 
for the financial year ended 31 December 2023



Screen Clinical Limited
DIRECTOR AND OTHER INFORMATION

 
Director Michael O'Neill
 
 
Company Registration Number NI642637
 
 
Registered Office and Business Address 16 Tobermore Road
Draperstown
Magherafelt
BT45 7HG
 
 
Accountants Quarter
Chartered Accountants
St.Annes House
Cathedral Quarter
15 Church Street
Belfast
County Antrim
BT1 1PG
United Kingdom



Screen Clinical Limited
DIRECTOR'S REPORT
for the financial year ended 31 December 2023

 
The director presents his report and the unaudited financial statements for the financial year ended 31 December 2023.
     
Director
The director who served during the financial year is as follows:
     
Michael O'Neill
   
There were no changes in shareholdings between 31 December 2023 and the date of signing the financial statements.
     
Political Contributions
The company did not make any disclosable political donations in the current financial year.
     
Statement of Director's Responsibilities
     
The director is responsible for preparing the Director's Report and the financial statements in accordance with applicable law and regulations.
     
Company law requires the director to prepare financial statements for each financial year. Under that law the director has elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law) including FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" Section 1A (Small Entities). Under company law the director must not approve the financial statements unless he is satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period.

In preparing these financial statements, the director is required to:
- select suitable accounting policies and apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.
     
The director is responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable him to ensure that the financial statements comply with the Companies Act 2006. He is also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.
     
Special provisions relating to small companies
The above report has been prepared in accordance with the special provisions relating to small companies within Part 15 of the Companies Act 2006.
     
     
On behalf of the board
     
     
___________________________
Michael O'Neill
Director
     
21 August 2024



Screen Clinical Limited
PROFIT AND LOSS ACCOUNT
for the financial year ended 31 December 2023
2023 2022
Notes £ £

Turnover 641,968 593,981
 
Cost of sales (328,779) (285,174)
───────── ─────────
Gross profit 313,189 308,807
 
Administrative expenses (293,282) (303,277)
───────── ─────────
Operating profit 19,907 5,530
 
Interest receivable and similar income 197 -
───────── ─────────
Profit before taxation 20,104 5,530
 
Tax on profit (3,820) 11,480
───────── ─────────
Profit for the financial year 16,284 17,010
    ═════════   ═════════



Screen Clinical Limited
Company Registration Number: NI642637
BALANCE SHEET
as at 31 December 2023

2023 2022
Notes £ £
 
Fixed Assets
Tangible assets 4 40,844 26,334
───────── ─────────
 
Current Assets
Debtors 5 108,378 130,851
Cash and cash equivalents 93,611 49,497
───────── ─────────
201,989 180,348
───────── ─────────
Creditors: amounts falling due within one year 6 (129,781) (80,914)
───────── ─────────
Net Current Assets 72,208 99,434
───────── ─────────
Total Assets less Current Liabilities 113,052 125,768
═════════ ═════════
 
Capital and Reserves
Called up share capital 100 100
Retained earnings 112,952 125,668
───────── ─────────
Equity attributable to owners of the company 113,052 125,768
═════════ ═════════
 
The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A (Small Entities).
           
For the financial year ended 31 December 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006.
           
The director confirms that the members have not required the company to obtain an audit of its financial statements for the financial year in question in accordance with section 476 of the Companies Act 2006.
           
The director acknowledges his responsibilities for ensuring that the company keeps accounting records which comply with section 386 and for preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of the financial year and of its profit and loss for the financial year in accordance with the requirements of sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.
           
Approved by the Director and authorised for issue on 21 August 2024
           
           
________________________________          
Michael O'Neill          
Director          
           



Screen Clinical Limited
NOTES TO THE FINANCIAL STATEMENTS
for the financial year ended 31 December 2023

   
1. General Information
 
Screen Clinical Limited is a company limited by shares incorporated and registered in Northern Ireland. The registered number of the company is NI642637. The registered office of the company is 16 Tobermore Road, Draperstown, Magherafelt, BT45 7HG which is also the principal place of business of the company. The principal activity of the company is the provision of services to compliment patient centered care The financial statements have been presented in Pound (£) which is also the functional currency of the company.
         
2. Summary of Significant Accounting Policies
 
The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.
 
Statement of compliance
The financial statements of the company for the financial year ended 31 December 2023 have been prepared in accordance with the provisions of FRS 102 Section 1A (Small Entities) and the Companies Act 2006.
 
Basis of preparation
The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention except for certain properties and financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets.
 
Turnover
Turnover comprises the invoice value of goods supplied by the company, exclusive of trade discounts and value added tax.
 
Tangible assets and depreciation
Tangible assets are stated at cost or at valuation, less accumulated depreciation. The charge to depreciation is calculated to write off the original cost or valuation of tangible assets, less their estimated residual value, over their expected useful lives as follows:
 
  Fixtures, fittings and equipment - 20% Reducing Balance
 
The carrying values of tangible fixed assets are reviewed annually for impairment in periods if events or changes in circumstances indicate the carrying value may not be recoverable.
 
Leasing
Rentals payable under operating leases are dealt with in the Profit and Loss Account as incurred over the period of the rental agreement.
 
Trade and other debtors
Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.
 
Trade and other creditors
Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.
 
Employee benefits
The company contributes to a stakeholder pension scheme on behalf of its employees
 
Taxation and deferred taxation
Current tax represents the amount expected to be paid or recovered in respect of taxable profits for the financial year and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Balance Sheet date.

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date where transactions or events have occurred at that date that will result in an obligation to pay more tax in the future, or a right to pay less tax in the future. Timing differences are temporary differences between the company's taxable profits and its results as stated in the financial statements. Deferred tax is measured on an undiscounted basis at the tax rates that are anticipated to apply in the periods in which the timing differences are expected to reverse, based on tax rates and laws that have been enacted or substantively enacted by the Balance Sheet date.
 
Foreign currencies
Monetary assets and liabilities denominated in foreign currencies are translated at the rates of exchange ruling at the Balance Sheet date. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated at the rates of exchange ruling at the date of the transaction. Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. The resulting exchange differences are dealt with in the Profit and Loss Account.
 
Ordinary share capital
The ordinary share capital of the company is presented as equity.
       
3. Employees
 
The average monthly number of employees, including director, during the financial year was 9, (2022 - 9).
 
  2023 2022
  Number Number
 
Director 1 1
Employee 8 8
  ───────── ─────────
  9 9
  ═════════ ═════════
       
4. Tangible assets
  Fixtures, Total
  fittings and  
  equipment  
  £ £
Cost
At 1 January 2023 43,755 43,755
Additions 22,174 22,174
  ───────── ─────────
At 31 December 2023 65,929 65,929
  ───────── ─────────
Depreciation
At 1 January 2023 17,421 17,421
Charge for the financial year 7,664 7,664
  ───────── ─────────
At 31 December 2023 25,085 25,085
  ───────── ─────────
Net book value
At 31 December 2023 40,844 40,844
  ═════════ ═════════
At 31 December 2022 26,334 26,334
  ═════════ ═════════
       
5. Debtors 2023 2022
  £ £
 
Trade debtors 101,522 120,175
Deferred tax asset 6,856 10,676
  ───────── ─────────
  108,378 130,851
  ═════════ ═════════
       
6. Creditors 2023 2022
Amounts falling due within one year £ £
 
Taxation  (Note 7) 15,932 13,244
Director's current account 67,334 49,353
Other creditors 17,728 4,594
Accruals 28,787 13,723
  ───────── ─────────
  129,781 80,914
  ═════════ ═════════
       
7. Taxation 2023 2022
  £ £
 
Creditors:
PAYE / NI 15,932 13,244
  ═════════ ═════════
       
8. Financial commitments
 
Total future minimum lease payments under non-cancellable operating leases are as follows:
 
  2023 2022
  £ £
Due:
Within one year 410 4,916
Between one and five years - 410
  ───────── ─────────
  410 5,326
  ═════════ ═════════
       
9. Capital commitments
 
The company had no material capital commitments at the financial year-ended 31 December 2023.
   
10. Director's advances, credits and guarantees
 
As at 31.12.2022 Screen Clinical Limited owned directors amount £49,353 and during the there was a net movement of £17,981 between Clinical Limited and directors and as at 31.12.2023 Screen Clinical Limited owned directors amount £67,334.
   
11. Post-Balance Sheet Events
 
There have been no significant events affecting the company since the financial year-end.